In a previous paper (1), the effect of streptococcal upper respiratory infections on groups of rheumatic children under close observation in a sanatorium was reported. It was found that during a three-year period no rheumatic relapses were observed in children who escaped streptococcal upper respiratory infections. Since, however, the total number of rheumatic recurrences was small, it seemed possible that the relationship of the streptococcal pharyngitis to the reactivation of the rheumatic process might have been accidental. To rule out this possibility, it was essential to study the effect of preventing streptococcal upper respiratory infections in rheumatic subjects by some means which had no immediate influence on the rheumatic infection itself. For this purpose, sulfanilamide was chosen, as most observers agree that this drug not only fails to benefit patients with active rheumatic fever, but actually tends to increase the severity of the rheumatic symptoms (2 to 4).
In a previous paper (1) , the effect of streptococcal upper respiratory infections on groups of rheumatic children under close observation in a sanatorium was reported. It was found that during a three-year period no rheumatic relapses were observed in children who escaped streptococcal upper respiratory infections. Since, however, the total number of rheumatic recurrences was small, it seemed possible that the relationship of the streptococcal pharyngitis to the reactivation of the rheumatic process might have been accidental. To rule out this possibility, it was essential to study the effect of preventing streptococcal upper respiratory infections in rheumatic subjects by some means which had no immediate influence on the rheumatic infection itself. For this purpose, sulfanilamide was chosen, as most observers agree that this drug not only fails to benefit patients with active rheumatic fever, but actually tends to increase the severity of the rheumatic symptoms (2 to 4).
On the other hand, the observations of Coburn and Moore and of Thomas and her coworkers indicated that prophylactic doses of sulfanilamide were effective in preventing streptococcal upper respiratory infections, and that rheumatic patients, so protected, escaped rheumatic relapses (5 to 9). These authors, however, did not have an opportunity of comparing the patients who were receiving sulfanilamide with a control group living under identical conditions, where exposure to Group A hemolytic streptococci could be determined. It seemed worthwhile, therefore, to study the value of sulfanilamide prophylaxis in an institution where the patients were under daily observation and careful bacteriological studies could be made.
The type of community, routine procedures, and 1 This work was aided by a grant from the Commonwealth Fund.
bacteriological methods used were the same as those previously described (1).
PLAN OF STUDY
During two successive winters, 1940 to 1941 and 1941 to 1942, the 108 rheumatic children at Irvington House were divided into 2 groups, matched as closely as possible in regard to age, sex, number of previous rheumatic attacks, and cardiac findings. Beginning in October 1940 and continuing until the following June, half of the children were given small daily doses of sulfanilamide. 2 The other 54 children served as controls. During the second winter, 1941 to 1942, 54 children were given sulfanilamide and 50 served as controls. Only children who showed neither clinical nor laboratory signs of rheumatic activity received this drug.
During the winter of 1940 to 1941, 78 per cent of the 108 patients were cases of possible and potential heart disease and 22 per cent had definite cardiac lesions. During the second winter, 1941 to 1942, the percentage of children in the group with organic heart disease was increased to 49 per cent. Of these 14 children-with definite rheumatic relapses, 4 had organic heart disease prior to these attacks and 10 did not. The rheumatic manifestations in 11 of these 14 patients (10 cases of possible and potential heart disease and 1 case of organic heart disease) were of short duration. Three children whose rheumatic symptoms persisted for several months had definite cardiac lesions.
Eight of the 14 rheumatic relapses followed pharyngitis o-f moderate severity. Four occurred in children who had mild upper respiratory symptoms, and 2 developed in patients in whom the diagnosis of the preceding pharyngitis was based only on laboratory data.
Four additional children of the 30 who had the Type 15 upper respiratory infection developed, following a latent period, distinct laboratory signs of rheumatic activity (leukocytosis and increased erythrocyte sedimentation rates which persisted for 1 month or more), but had no definite clinical symptoms, or changes in their X-ray or electrocardiographic findings, and therefore were classified as having questionable rheumatic recurrences. One of these children had received sulfanilamide originally but could not tolerate the drug; his routine throat culture revealed hemolytic streptococci 2 weeks after the withdrawal of sulfanilamide. He had no complaints or symptoms but his antistreptolysin 0 titer rose, and his erythrocyte sedimentation rate remained elevated for 6 weeks. Beginning October 26th and continuing until the middle of January 1942, 17 children in the control group of 50 developed pharyngitis due to a streptococcus which appeared identical with the strain isolated from H. B. Rabbits were immunized with this microorganism, designated as B35, isolated from one of these patients; and with their sera used in slide agglutination (Griffith) and anti M precipitin tests (Lancefield), the strains isolated from the 17 cases of pharyngitis, as well as the one obtained from H. B. on admission, were shown to represent a single serological type, designated as streptococcus B35 in the remainder of this paper."
The spread of streptococcus B35 was more rapid than that observed in previous outbreaks of streptococcal pharyngitis: 6 cases occurred in October and 9 in November, followed by 1 in December and 1 in January. Thirteen of these 17 cases were of moderate severity with'rectal temperatures of 1010 F. or more. In 2 patients, the symptoms were mild. Two children had neither complaints nor symptoms and the diagnosis of pharyngitis was based on laboratory findings.
Incidence of rheumatic recurrences in the control group, 1941 to 1942 Following a latent period varying from 10 to 18 days, 9 of these 18 children developed definite rheumatic recurrences and one a questionable rheumatic recurrence. Of these 10 children with rheumatic manifestations, 6 had organic heart disease previous to these attacks and 4 were cases of possible and potential heart disease. The rheumatic recurrences in 4 of these 10 children were severe (pericardial friction rub, subcutaneous nodules, persistent high fever). Of these 4, 3 had organic heart disease prior to these attacks and one did not. During the second year, 1941 to 1942, the group receiving sulfanilamide consisted of 23 children who had taken the drug during the previous winter and 31 new patients. Among these 31 children, 5 were unable to tolerate the drug. Thus, of the total of 100 patients given prophylactic doses of sulfanilamide, toxic reactions developed in 15.
Similar toxic reactions were encountered during the two successive years: namely, fever, nausea and vomiting, skin manifestations, and leukopenia. The age, weight, dosage, and symptoms of the 15 children who developed toxic manifestations are summarized in Table III .
The most frequent toxic reaction was fever, in several instances accompanied by abdominal pain and vomiting. This reaction developed in 7 patients between the 5th and 13th day of medication after 10 to 26 grams of the drug had been given.
Five children developed skin manifestations. In 4 of them, this symptom appeared between the 11th and 15th days of medication when 11 to 14.5 grams of sulfanilamide had been taken. In 2 children, the rash was erythematous and the leukocyte count and temperature remained normal. In 2 others, the rash was urticarial and was accompanied by leukocytosis. One of these 2 children was afebrile. In the other, the urticaria was less extensive and the drug was not discontinued immediately; but 2 days later, this patient developed a temperature of 1030 F. and the medication was *stopped. In the 5th child, Number 9, Table III, the rash was also urticarial but did not develop until the 31st day of medication when a total of 70 grams had been taken. This patient had a temperature of 1000 F. and a slightly elevated leukocyte count.
Leukopenia developed in 3 patients, after 3 to 4 weeks, when they had received 21 to 28 grams of sulfanilamide. The total number of white blood cells, as well as the percentage of polymorphonuclears, decreased gradually.
Results obtained by retesting patients who had developed toxic manifestations
In order to prove that the symptoms or blood changes observed were really due to sulfanilamide, the drug was restarted in 9 of these patients after intervals of 8 days to 18 months. Another patient, not included in Table III , is also worth mentioning. A boy developed an extensive, itching, urticarial rash after receiving sulfanilamide for 21/2 months. He had no fever and the leukocyte count was within normal limits. This patient had no history of asthma, hay fever, or food allergy. The drug was discontinued and the urticaria disappeared within 48 hours. After 2 weeks, this boy was restarted on 0.3 gram of sulfanilamide a day. The dose was increased gradually to 1.3 grams a day and then maintained for 4 months with no untoward effect.
Two patients, Numbers 6 and 7, Table III , who had developed leukopenia, again showed similar changes in the blood picture, with the same dosage, in approximately the same length of time.
Thus of 9 children retested, 7 again developed symptoms and 2 did not. It may be that the reactions originally observed in these 2 patients were not due to sulfanilamide. On the other hand, it also seems possible that the toxic manifestations were transient and did not recur when the drug was given more slowly.
Four of the 5 children who could not tolerate the drug during the winter of 1941 to 1942 were subsequently given sulfadiazine.4 One boy developed symptoms identical with those caused by sulfanilamide, namely, fever and abdominal pain. The other 3 children tolerated sulfadiazine.
General condition of children receiving prophylactic doses of sulfanilamide The children who did not develop toxic manifestations within 5 weeks tolerated the drug well. There were no subjective complaints. In most instances, the patients continued to gain weight at the same rate as before medication was started. The weight gain in children receiving sulfanilamide was comparable to that of children in the control group. Cyanosis was noticeable only in a few light-complexioned patients. Minor transitory toxic reactions Leukocyte count and hemoglobin determinations were made once a week on every child receiving sulfanilamide. The total red cells were determined every 2 weeks, or oftener when indicated.5
It was found that the hemoglobin of most children receiving sulfanilamide tended to fall slightly and remained at a level somewhat lower than normal throughout the course of treatment. When the drug was discontinued, the hemoglobin rose to its previous level. In one instance, a boy of 12 years, weighing 79 lbs., with typical mitral stenosis, received 1 gram of sulfanilamide a day. His hemoglobin dropped from 14.5 to 10.5 grams per 100 cc. during the first week of medication. At the same time, his hematocrit reading fell from 42 to 32 per cent and his red blood count from 4,820,000 to 3,100,000 cells. He had no complaints, no jaundice, and normal urine findings. His blood sulfanilamide level was 1 mgm. per cent. Since he had no clinical symptoms and because a blood level of 1 mgm. per cent was considered insufficient to protect him from streptococcal pharyngitis, the dosage was increased to 1.3 grams a day.
Within a week his hemoglobin, hematocrit reading, and red blood count began to rise. Thereafter, his hemoglobin ranged between 13 to 14 grams and his red blood count between 3,900,000 to 4,510,000 cells.
Minor fluctuations in the total leukocyte count and percentage of polymorphonuclears were also observed. In most instances, these changes were no greater than those encountered from time to time among children in the control group. An outbreak of upper respiratory' infections of unknown etiology, accompanied by leukopenia, occurred in the institution during April and May 1942. With a few exceptions, sulfanilamide was not discontinued. The fall in leukocyte count in children receiving sulfanilamide and that in the control group were equally striking. However, the leukopenia tended to persist for a slightly longer period in patients receiving the drug.
The effect on the incidence of rheumatic relapses of preventing streptococcal upper respiratory infections by the prophylactic use of sulfanilamide is reported. Small daily doses of the drug were given to half of a group of rheumatic children under close observation in a sanatorium from October until June, during 2 successive winters. The contrast between the incidence of streptococcal upper respiratory infections and rheumatic relapses in the treated and untreated groups was clear-cut. Of the 108 children receiving sulfanilamide, only 2 children contracted streptococcal upper respiratory infections, and only one of these 2 patients showed signs of rheumatic activity. Among the 104 children who served as controls, 48 contracted streptococcal pharyngitis, and 23 of these, or 48 per cent, developed definite rheumatic relapses, and 5 additional children had laboratory evidence or mild symptoms suggesting rheumatic activity. In accord with our previous experience, no rheumatic relapses were observed in children who escaped streptococcal upper respiratory infections (1) .
Evidence that rheumatic relapses usually follow in the wake of upper respiratory infections associated with Group A hemolytic streptococci had been accumulating for many years. The high incidence of rheumatic fever and rheumatic recurrences following outbreaks of tonsillitis in schools and training camps, as well as in convalescent homes for rheumatic children (10 to 14), suggested that streptococci might play a role in the etiology of this disease.
It is now well known that rheumatic relapses follow mild as well as severe cases of streptococcal pharyngitis. The symptoms of the upper respiratory infection may indeed be so slight as to be completely forgotten by ambulatory patients at the time that the rheumatic manifestations appear. Even in convalescent homes, cases of streptococcal pharyngitis may be overlooked unless careful bacteriological and serological studies are made. It is not surprising, therefore, that some observers have been inclined to doubt the importance of the relationship between streptococcal pharyngitis and rheumatic fever..
With the advent of sulfanilamide, a specific means of preventing streptococcal upper respiratory infections in rheumatic subjects became available. The studies of Coburn and Moore, and Thomas and her coworkers, indicated that the prevention of streptococcal pharyngitis also prevented rheumatic relapses. However, nearly all the patients included, in the series of Thomas, et al., were more than 14 years of age, when the incidence of rheumatic recurrences tends to decline spontaneously. In Coburn and Moore's studies, most of the children were ambulatory and the degree of exposure to Group A hemolytic streptococci could not be determined so accurately as among patients living in an institution. In our series, the incidence of streptococcal upper respiratory infections was high among the children in the control group, and nearly 50 per cent of those so infected developed rheumatic sequelae. Our results are in accord with those mentioned above and suggest that in closed communities where the spread of streptococci is difficult to control, prophylactic doses of sulfanilamide are effective in preventing both streptococcal pharyngitis and rheumatic relapses. Furthermore, these studies, aside from showing the prophylactic value of sulfanilamide, indicate that the relationship between streptococcal upper respiratory infections and the reactivation of the rheumatic process is specific, and therefore establish the importance of Group A hemolytic streptococci as a factor in the etiology of rheumatic fever.
Although the course of rheumatic fever in certain individuals is insidious, severe cardiac damage is usually the result of repeated rheumatic relapses (15) . The chief aim therefore of the physician who has rheumatic patients under his care, should be the prevention of rheumatic recurrences. The effectiveness of prophylactic sulfanilamide in preventing rheumatic relapses has been established by our findings as well as those of others. In considering any prophylactic measure, however, the inherent danger must be carefully weighed.
The two most serious toxic reactions which have been reported during the course of sulfanilamide therapy are: acute hemolytic anemia and acute agranulocytosis. To date, hemolytic anemia has not been described in patients receiving prophylactic doses of sulfanilamide.
One instance of a fatal acute agranulocytosis, however, has been reported by Stowell and But-ton (16) . A boy of 12 years developed this complication after receiving 0.6 gram three times a day for 29 days. Acute agranulocytosis is rare in patients receiving sulfanilamide therapy. It occurs most commonly between the 17th and 25th day of treatment but may appear as early as the 14th and as late as the 70th day, and is independent of dosage (17, 18) . Acute agranulocytosis develops suddenly and probably represents a peculiar idiosyncrasy to sulfanilamide. The possibility of this complication in patients receiving prophylactic-sulfanilamide must always be borne in mind and constitutes the greatest hazard of this form of treatment.
The incidence of toxic reaction in our series (15 per cent) was higher than that reported by Coburn and Moore (6) . No serious reactions were encountered. Even though smaller doses were used during the second winter than during the first, the incidence of toxic reaction was not reduced. It is our impression that in most instances the development of toxic reactions is due to an idiosyncrasy of the individual, rather than to the size of the dose. Twenty-three patients who received sulfanilamide during two successive winters showed no evidence of sensitization when the drug was restarted after a lapse of nearly 5 months.
In one instance, a blood level of 2 mgm. per cent was insufficient to prevent streptococcal pharyngitis. A similar failure was encountered in a patient with a blood level of 0.95 mgm. per cent. It seems possible that the child with the level of 2 mgm. per cent who contracted the streptococcal infection, was either very susceptible to the particular streptococcus or that the infecting dose was unusually large. In most instances, a blood level of 2 mgm. per cent seems to be adequate. On the other hand, we are of the opinion that a blood level of 1 mgm. per cent is probably too low to be effective.
The ultimate value of prophylactic sulfanilamide can be determined only by protecting rheumatic individuals from streptococcal upper respiratory infections for long periods of time. The prolonged administration of any drug as toxic as sulfanilamide may eventually prove harmful even in patients who apparently tolerate the drug. Furthermore, individuals who have been protected against infection with Group A hemolytic streptococci for many years may be extremely susceptible to these microorganisms when sulfanilamide is withdrawn.
On the other hand, the prognosis in patients with severe rheumatic heart disease is so poor as to justify taking risks. In our opinion, at the present stage of our knowledge, the effect of the prolonged administration of sulfanilamide should first be tried in this type of case.
To date, no reports have appeared on the prophylactic use of sulfadiazine in preventing streptococcal upper respiratory infections; and our own experience is too limited to warrant drawing conclusions. It seems likely that this drug will prove as effective as sulfanilamide.
Although it now seems established that Group A hemolytic streptococci play a part in precipitating rheumatic recurrences, the mode of action of these microorganisms in this disease remains obscure. It is possible that as our knowledge of the immunological response of individuals to streptococcal infections increases, new methods of combatting streptococci, based on biological reactions rather than on chemotherapy, will be devised. 2. Toxic manifestations of sufficient severity to necessitate the withdrawal of the drug occurred in 15 per cent of the patients.
3. Children, who did not develop toxic reactions, tolerated the drug well.
4. The effectiveness of sulfanilamide in preventing rheumatic recurrences indicates that infection with Group A hemolytic streptococci is an important factor in the etiology of rheumatic fever.
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